POSEIDA THERAPEUTICS INC (PSTX) Stock Price, Quote, News and Overview
NASDAQ:PSTX - Nasdaq - US73730P1084 - Common Stock - Currency: USD
PSTX Quote, Performance and Key Statistics
9.5
-0.06 (-0.63%)
The current stock price of PSTX is 9.5 USD. In the past month the price increased by 1.5%. In the past year, price increased by 211.48%.
PSTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.76 | 318.03B | ||
| AMGN | AMGEN INC | 14.15 | 150.84B | ||
| GILD | GILEAD SCIENCES INC | 23.28 | 133.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698.55 | 126.63B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.13 | 65.51B | ||
| ARGX | ARGENX SE - ADR | 324.33 | 36.83B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.37B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.90B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.79B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 25.15B | ||
| NTRA | NATERA INC | N/A | 20.44B | ||
| BIIB | BIOGEN INC | 7.24 | 17.46B |
Related stock screener links
About PSTX
Company Profile
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2020-07-10. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.
Company Info
POSEIDA THERAPEUTICS INC
9390 Towne Centre Drive, Suite 200
San Diego CALIFORNIA 92121 US
CEO: Eric Ostertag
Employees: 337
Company Website: https://poseida.com/
Investor Relations: https://investors.poseida.com/
Phone: 18587793100
POSEIDA THERAPEUTICS INC / PSTX FAQ
What is the stock price of POSEIDA THERAPEUTICS INC today?
The current stock price of PSTX is 9.5 USD. The price decreased by -0.63% in the last trading session.
What is the ticker symbol for POSEIDA THERAPEUTICS INC stock?
The exchange symbol of POSEIDA THERAPEUTICS INC is PSTX and it is listed on the Nasdaq exchange.
On which exchange is PSTX stock listed?
PSTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for POSEIDA THERAPEUTICS INC stock?
10 analysts have analysed PSTX and the average price target is 9.18 USD. This implies a price decrease of -3.37% is expected in the next year compared to the current price of 9.5. Check the POSEIDA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is POSEIDA THERAPEUTICS INC worth?
POSEIDA THERAPEUTICS INC (PSTX) has a market capitalization of 925.97M USD. This makes PSTX a Small Cap stock.
How many employees does POSEIDA THERAPEUTICS INC have?
POSEIDA THERAPEUTICS INC (PSTX) currently has 337 employees.
What are the support and resistance levels for POSEIDA THERAPEUTICS INC (PSTX) stock?
POSEIDA THERAPEUTICS INC (PSTX) has a support level at 9.5 and a resistance level at 9.51. Check the full technical report for a detailed analysis of PSTX support and resistance levels.
Is POSEIDA THERAPEUTICS INC (PSTX) expected to grow?
The Revenue of POSEIDA THERAPEUTICS INC (PSTX) is expected to grow by 217.39% in the next year. Check the estimates tab for more information on the PSTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy POSEIDA THERAPEUTICS INC (PSTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PSTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PSTX, evaluating the profitability, health, valuation and growth aspects
- POSEIDA THERAPEUTICS INC (PSTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- POSEIDA THERAPEUTICS INC (PSTX) Sales and EPS estimates to see what analysts future expectations are.
- POSEIDA THERAPEUTICS INC (PSTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- POSEIDA THERAPEUTICS INC (PSTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- POSEIDA THERAPEUTICS INC (PSTX) Stock Chart to make your own analysis
- POSEIDA THERAPEUTICS INC (PSTX) Latest news and press-releases to stay up to date.
Does POSEIDA THERAPEUTICS INC (PSTX) stock pay dividends?
PSTX does not pay a dividend.
What is the Price/Earnings (PE) ratio of POSEIDA THERAPEUTICS INC (PSTX)?
POSEIDA THERAPEUTICS INC (PSTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.63).
PSTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PSTX. When comparing the yearly performance of all stocks, PSTX is one of the better performing stocks in the market, outperforming 98.96% of all stocks.
PSTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PSTX. PSTX may be in some trouble as it scores bad on both profitability and health.
PSTX Financial Highlights
Over the last trailing twelve months PSTX reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 58.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.7% | ||
| ROE | -69.67% | ||
| Debt/Equity | 0.68 |
PSTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 50% to PSTX. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 30.29% and a revenue growth 217.39% for PSTX